Kim N. Chi, MD | Authors


Apalutamide Combination is Well Tolerated in Metastatic Castration-Sensitive Prostate Cancer

September 10, 2019

Kim N. Chi, MD, discusses the safety findings for the next-generation androgen receptor inhibitor apalutamide in combination with androgen deprivation therapy in patients with metastatic castration-sensitive prostate cancer, according to findings from the phase III TITAN study. This combination was compared with placebo and ADT and presented at the 2019 ASCO Annual Meeting.